Synthetic Biologics, Inc. (SYN): Price and Financial Metrics
GET POWR RATINGS... FREE!
SYN Stock Price Chart Interactive Chart >
SYN Price/Volume Stats
| Current price | $0.22 | 52-week high | $0.72 |
| Prev. close | $0.21 | 52-week low | $0.20 |
| Day low | $0.21 | Volume | 238,300 |
| Day high | $0.22 | Avg. volume | 2,369,675 |
| 50-day MA | $0.26 | Dividend yield | N/A |
| 200-day MA | $0.33 | Market Cap | 34.56M |
Synthetic Biologics, Inc. (SYN) Company Bio
Synthetic Biologics, Inc. is a clinical stage company developing therapeutics which protect microbiomes and target pathogen-specific diseases. The Company develops drugs that are designed to reduce the impact of methane-producing organisms to help treat the cause of IBS-C and designed to protect microbiomes and prevent CDI during IV antibiotic use.
Latest SYN News From Around the Web
Below are the latest news stories about Synthetic Biologics Inc that investors may wish to consider to help them evaluate SYN as an investment opportunity.
Synthetic Biologics to Present at 2022 BIO CEO & Investor ConferenceSynthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that the Company will be presenting at the 2022 BIO CEO & Investor Conference being held February 14-17, 2022. The conference will be conducted as a hybrid event at the New York Marriott Marquis and virtually. |
Synthetic Biologics says VCN's therapy for retinoblastoma gets FDA's orphan drug statusSynthetic Biologics (NYSE:SYN) said VCN Biosciences' VCN-01 received the U.S. Food & Drug Administration's (FDA) orphan drug designation for retinoblastoma, a type of eye cancer. Synthetic Biologics is in the process of acquiring VCN. "We are highly encouraged by the preliminary clinical data thus far and look forward to conducting a pivotal Phase 2/3 trial... |
Synthetic Biologics Announces VCN Biosciences'' VCN-01 Receives Orphan Drug Designation for Retinoblastoma from the U.S. FDAROCKVILLE, Md., Feb. 8, 2022 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that VCN Biosciences, S.L.''s (VCN) VCN-01 received Orphan Drug… |
Synthetic Biologics says VCN''s therapy for retinoblastoma gets FDA''s orphan drug statusSynthetic Biologics (SYN) said VCN Biosciences'' VCN-01 received the U.S |
Synthetic Biologics Announces VCN Biosciences' VCN-01 Receives Orphan Drug Designation for Retinoblastoma from the U.S. FDASynthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that VCN Biosciences, S.L.'s (VCN) VCN-01 received Orphan Drug Designation for retinoblastoma from the U.S. Food & Drug Administration (FDA). This announcement follows Synthetic Biologics' recent announcement that it had entered a definitive agreement to acquire VCN, which is subject to conditions that must be met pri |
SYN Price Returns
| 1-mo | -10.75% |
| 3-mo | -7.56% |
| 6-mo | -36.23% |
| 1-year | -58.10% |
| 3-year | -59.75% |
| 5-year | -98.97% |
| YTD | -19.18% |
| 2021 | -28.93% |
| 2020 | -24.44% |
| 2019 | -9.48% |
| 2018 | -96.86% |
| 2017 | -32.89% |
Loading social stream, please wait...